10-K · March 12, 2026
Rapid Micro Biosystems’ 2025 10-K emphasizes commercialization of its Growth Direct MQC platform (190 systems placed; ~9 million consumables sold) and reports continued revenue growth (sum of 2025 quarters = $33.0M vs…
Earnings analysis · 10-Q
RPID earnings analysis
Filed May 15, 2026 · Our reading of the company's report
The latest report
Rapid Micro Biosystems reported Q1 2026 results with revenue of $8.0 million, surpassing estimates and marking an 11.1% increase year-over-year. However, the company reported an EPS loss of -$0.31, missing expectations…
Read full summary
Rapid Micro Biosystems reported Q1 2026 results with revenue of $8.0 million, surpassing estimates and marking an 11.1% increase year-over-year. However, the company reported an EPS loss of -$0.31, missing expectations due to rising operating losses and expenses.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.31
- Gross margin
- 4.6%
- Segment
- Product revenue $5,578M, Service revenue $2,424M
What stood out
-
Revenue Growth Exceeds Estimates
Revenue reached $8.0 million, exceeding the estimated $7.58 million and showing an 11.1% increase from $7.2 million in Q1 2025.
-
Product Revenue Surge
Product revenue increased by $1.5 million, or 36.0%, driven by higher system placements and consumable shipments.
-
Recurring Revenue Improvement
Recurring revenue grew 27.7% to $5.1 million, constituting 63.3% of total revenue, up from 55.1% in Q1 2025.
-
Positive Gross Margin Trend Continues
Gross margin improved to 4.6% for Q1 2026, up from 3.1% in Q4 2025.
-
Strong Capital Structure
Cash and cash equivalents as of March 31, 2026, stood at $13.8 million, with total assets of $23.2 million.
-
Long-Term Growth Outlook Reaffirmed
The company reiterated full-year 2026 revenue guidance of $37 million to $41 million, with an expected gross margin around 20%.
What to watch
-
Increased Operating Losses
Net loss rose to $14.3 million in Q1 2026, compared to $11.3 million in Q1 2025, driven by higher operational costs.
-
Cash Flow Concerns
Operating cash flows worsened with net cash used at $15.1 million, increasing from $9.1 million in Q1 2025.
-
Debt Servicing Under Pressure
Interest expense jumped to $639,000 from $12,000 in the previous year due to new long-term debt incurred.
Management's outlook
Maintains revenue guidance of $37M-$41M for 2026; strong outlook pending ongoing growth in product placements.
Earlier filings 4
10-Q · November 7, 2025
Rapid Micro Biosystems reported Q3 revenue of $7,838,000, up from $7,604,000 in Q3 2024, with gross margin improving to ~8.9% and a slightly narrower operating loss of $(11,372,000) vs $(12,039,000) a year earlier.…
10-Q · August 12, 2025
Rapid Micro Biosystems reported Q2 2025 revenue of $7,262,000, up 9.7% year-over-year and modestly (+$57,000) versus Q1 2025. Gross profit was $275,000 (3.8% margin) but operating loss remained large at $(12,148,000),…
10-Q · May 9, 2025
Rapid Micro Biosystems reported Q1 revenue of $7,205,000 (vs $5,611,000 in Q1 2024), driving year-over-year revenue growth and a swing to a positive gross margin of 5.6%. Operating loss narrowed to $(11,661,000) and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.